Related Experiment Video
Updated: Aug 9, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
International study on low-grade primary central nervous system lymphoma
Kristoph Jahnke1, Agnieszka Korfel, Brian Patrick O'Neill
1Department of Hematology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany. kristophe.jahnke@charite.de
Objective:
The aim of this study was to characterize the clinical presentation, course, and outcome of low-grade primary central nervous system lymphoma.
Methods:
Cases were assessed in a retrospective series collected from 18 cancer centers in 5 countries.
Results:
Forty patients (18 men, 22 women; median age, 60 years [range, 19-78]) were identified. Involvement of a cerebral hemisphere or deeper brain structures was seen in 37 patients, only leptomeningeal involvement in 2 patients, and spinal cord disease in 1 patient. Chemotherapy/radiotherapy was conducted in 15 patients, radiotherapy alone in 12, chemotherapy alone in 10, and tumor resection alone in 2, whereas 1 patient received no treatment. The median progression-free, disease-specific, and overall survival were 61.5 (range, 0-204), 130 (range, 1-204), and 79 (range, 1-204) months, respectively. Only age 60 years or older was associated with shorter progression-free (p = 0.009), disease-specific (p = 0.015), and overall survival (p = 0.001) in multivariate analysis.
Interpretation:
Low-grade primary central nervous system lymphoma differs from the high-grade subtype in its pathological, clinical, and radiological features. It has a better long-term outcome than primary central nervous system lymphoma in general with age 60 years or older adversely affecting survival.
